Similar articles for PMID: 22514793

Year	Number of Results
1991	1
1996	2
1997	3
1998	3
1999	1
2000	6
2001	2
2002	3
2003	2
2004	4
2005	6
2006	5
2007	3
2008	3
2009	1
2010	5
2011	7
2012	5
2013	7
2014	5
2015	5
2016	6
2017	5
2018	4
2019	3
2020	2
2021	5
2022	2
2023	2
2024	0

1

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.

Allegri RF, Guekht A. Allegri RF, et al. Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721. Drugs Today (Barc). 2012. PMID: 22514793 Review.

2

Cerebrolysin: a review of its use in dementia.

Plosker GL, Gauthier S. Plosker GL, et al. Drugs Aging. 2009;26(11):893-915. doi: 10.2165/11203320-000000000-00000. Drugs Aging. 2009. PMID: 19848437 Review.

3

[Pharmacological approaches to the therapy of Alzheimer's disease].

Gavrilova SI. Gavrilova SI. Vestn Ross Akad Med Nauk. 2006;(9-10):30-4. Vestn Ross Akad Med Nauk. 2006. PMID: 17111921 Russian.

4

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H. Alvarez XA, et al. Eur J Neurol. 2011 Jan;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x. Eur J Neurol. 2011. PMID: 20500802 Clinical Trial.

5

Spotlight on cerebrolysin in dementia.

Plosker GL, Gauthier S. Plosker GL, et al. CNS Drugs. 2010 Mar;24(3):263-6. doi: 10.2165/11204820-000000000-00000. CNS Drugs. 2010. PMID: 20155999

6

Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.

Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Gauthier S, et al. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi: 10.1159/000377672. Epub 2015 Mar 26. Dement Geriatr Cogn Disord. 2015. PMID: 25832905 Free article.

7

Cerebrolysin for vascular dementia.

Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Chen N, et al. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD008900. doi: 10.1002/14651858.CD008900.pub2. Cochrane Database Syst Rev. 2013. PMID: 23440834 Updated. Review.

8

Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.

Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Guekht AB, et al. J Stroke Cerebrovasc Dis. 2011 Jul-Aug;20(4):310-8. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.012. Epub 2010 Jul 24. J Stroke Cerebrovasc Dis. 2011. PMID: 20656516 Clinical Trial.

9

Cerebrolysin in Alzheimer's disease.

Antón Álvarez X, Fuentes P. Antón Álvarez X, et al. Drugs Today (Barc). 2011 Jul;47(7):487-513. doi: 10.1358/dot.2011.47.7.1656496. Drugs Today (Barc). 2011. PMID: 22013558

10

Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.

Thome J, Doppler E. Thome J, et al. Drugs Today (Barc). 2012 Apr;48 Suppl A:63-9. doi: 10.1358/dot.2012.48(Suppl.A).1739724. Drugs Today (Barc). 2012. PMID: 22514795 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year